Root Admin Guide Posted January 4, 2019 Root Admin Report Share Posted January 4, 2019 Gallo et al whose research published in Nature Medicine in 2007 that suggested "an explanation for the pathogenesis of rosacea by demonstrating that an exacerbated innate immune response can reproduce elements of this disease" involving cathelicidin (particularly Peptide LL-37), Vitamin D3, and Alarmins has applied for a patent (United States Patent Application 20160030386), PREVENTION OF ROSACEA INFLAMMATION. [1] The patent is a long read and not for the timid or shy to read through. The nutshell version is a patent for treating rosacea inflammation with mast cell stabilizers, (ie., lodoxamide, nedocromil, cromolyn, pemirolast, pharmaceutical salts), as well as, neuropetide antagonists, a serine protease inhibitor, a vitamin D3 antagonist, including combinations of these treatments. End Notes [1] Images and tables/graphs with resultshttp://www.freepatentsonline.com/20160030386.pdf Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now